Showing 741-750 of 2293 results for "".
- Black People May Respond Differently to Anti-CD20 Treatment for Multiple Sclerosishttps://practicalneurology.com/news/black-people-may-respond-differently-to-anti-cd20-treatment-for-multiple-sclerosis/2469561/A preliminary retrospective study suggests Black people may respond differently to antiCD20 treatments commonly used to treat multiple sclerosis (MS) or neuromyelitis optica spectrum disorder (NMOSD). After treatment with B-cell depleting antiCD20 agents rituximab or ocrelizumab via infusion, Bla
- FDA Gives Marketing Authorization to Translingual Neuromodulation Device for Treatment of Gait Deficits in Multiple Sclerosishttps://practicalneurology.com/news/fda-gives-marketing-authorization-to-translingual-neuromodulation-device-for-treatment-of-gait-deficits-in-multiple-sclerosis/2469546/The Food and Drug Administration (FDA) authorized marketing of a tongue-delivered portable neuromodulation device (PoNS; Helius Medical, Newtown, PA) to treat gait deficit caused by multiple sclerosis (MS). The device is a prescription only adjunct to a supervised therapeutic exercise program for
- FDA Approves Ponesimod for Relapsing Multiple Sclerosishttps://practicalneurology.com/news/fda-approves-ponesimod-for-relapsing-multiple-sclerosis/2469532/The Food and Drug Administration (FDA) has approved ponesimod (Ponvory; Janssen, Titusville, NJ) for the treatment of relapsing forms of multiple sclerosis (MS). Ponesimode is an oral medication, taken once daily. In a randomized double-blind head-to-head phase 3 clinical trial (
- Multiple Sclerosis Symptoms May Worsen With Higher Than Average Temperatureshttps://practicalneurology.com/news/multiple-sclerosis-symptoms-may-worsen-with-higher-than-average-temperatures/2469518/A preliminary study reveals that in months when the average environmental temperature was higher than the long-term average by 2 degrees Fahrenheit, people with multiple sclerosis (MS) had an increased rate of hospital service use. During periods of anomalously wa
- Continued Use of Disease-Modifying Therapy During Pregnancy May Reduce Hospitalizationhttps://practicalneurology.com/news/continued-use-of-disease-modifying-therapy-during-pregnancy-may-reduce-hospitalization/2469515/Results of a study from AllianceRx Walgreens Prime showed individuals with multiple sclerosis (MS) who are pregnant typically reduce use of disease-modifying therapies (DMTs). A significant number, however, continue treatment with high adherence levels (proportion of days covered [PDC] ≥.80).
- Reassuring Evidence of Antibody Response During Treatment With Cladribine for Multiple Sclerosishttps://practicalneurology.com/news/reassuring-evidence-of-antibody-response-during-treatment-with-cladribine-for-multiple-sclerosis/2469511/Individuals with relapsing multiple sclerosis (MS) who were vaccinated against varicella zoster virus (VZV; n=3) before, or seasonal influenza (n=12) after a first course of treatment with cladribine (MAVENCLAD; EMD Serono; Rockland, MA) retained effective antibody titers against those viruses. I
- European Clinical Show Nabiximols Treatment Reduces Spasticity in Multiple Sclerosis Without Affecting Muscle Strength or Walking Speedhttps://practicalneurology.com/news/european-clinical-show-nabiximols-treatment-reduces-spasticity-in-multiple-sclerosis-without-affecting-muscle-strength-or-walking-speed/2469429/Data from 3 European randomized placebo-controlled clinical trials of nabiximols (Sativex; GW Pharmaceuticals, Carlsbad, CA) for spasticity in multiple sclerosis (MS) were presented at the American Academy of Physical Medicine and Rehabilitation (AAPMR) Annual Assembley. Nabiximols is derived fro
- Cannabis-Derived Nabiximols Well-Tolerated and Effective for Spasticity in Multiple Sclerosishttps://practicalneurology.com/news/cannabis-derived-nabiximols-well-tolerated-and-effective-for-spasticity-in-multiple-sclerosis/2469385/Nabiximols (Greenwich Biosciences, Carlsbad, CA) is approved for use as Sativex in over 25 countries, but not the US, for treatment of spasticity in multiple sclerosis (MS). Nabiximols is a chemically complex extract of the cannabis plant, consistently produced under controlled conditions and adm
- Expanded Disability Status Scale Available on Digital Platformhttps://practicalneurology.com/news/expanded-disability-status-scale-available-on-digital-platform/2469321/The proprietary platform (eCOA Pathway; VeraSci, Durham, NC) has been expanded to fully integrate the Expanded Disability Status Scale (EDSS) assessment and Neurostatus data clarification services for MS trials. VeraSci partnered with Dr. Marcus D'Souza and professor Ludwig Kappos at Neurosta
- Enrollment Begins for Phase 1b Clinical Trial of T-cell Immunotherapy for Progressive Multiple Sclerosishttps://practicalneurology.com/news/enrollment-begins-for-phase-1b-clinical-trial-of-t-cell-immunotherapy-for-progressive-multiple-sclerosis/2469303/The first participant has been enrolled in a phase 1b study of the allogeneic EBV T-cell immunotherapy (ATA188; Atara Biotherapeutics, South San Francisco, CA), for individuals with progressive forms of multiple sclerosis (MS). Participants in clinical sites across the US and Australia